WAVEMAN · COMPANY

IRMD · Iradimed Corp

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

IRMD

Name: IRADIMED CORP (IRMD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

IRADIMED CORP

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001325618

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$8.9M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

114

13F, latest reported quarter

REVENUE GROWTH

+14.4%

XBRL, annual

NET MARGIN

26.8%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$8.9M over 180 days

-$8.6M of it by a 10%+ holder

below 83% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

114 funds added or opened last quarter

more than 60% of Medical Devices

REVENUE

+14.4% year over year

more than 64% of Medical Devices

MARGIN

26.8% net margin

more than 96% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

5.2% of shares outstanding short · 5.8 days to cover · settled 2026-07-31

more than 65% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

114 funds added or opened positions in the latest 13F quarter, of 214 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +22.6%

+22.6%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $8.9M sold by insiders over 180 days, 114 funds added last quarter, $122.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, IRADIMED CORP insiders sold a net $8.9M of stock across 291 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Scharen-Guivel Hilda Frederique

Director

SELL

2026-06-04

1,766.0

$167.8K

Scharen-Guivel Hilda Frederique

Director

SELL

2026-06-04

1,234.0

$117.2K

Susi Roger E.

CEO, President, Chairman

SELL

2026-06-01

401.0

$36.5K

Susi Roger E.

CEO, President, Chairman

SELL

2026-06-01

775.0

$69.6K

Susi Roger E.

CEO, President, Chairman

SELL

2026-06-01

400.0

$35.5K

291 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 286 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

967,825.0 sh

$92.5M

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC

396,982.0 sh

$37.9M

RENAISSANCE TECHNOLOGIES LLC

394,412.0 sh

$37.7M

Copeland Capital Management, LLC

391,860.0 sh

$37.4M

VANGUARD CAPITAL MANAGEMENT LLC

364,937.0 sh

$34.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Monty K. Allen

FILED 2026-09-03

$122.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Ranger Micro Cap Fund

$327.9K POSITION · AS OF 2026-04-30

2.8%

Virtus KAR Small-Cap Growth Fund

$13.4M POSITION · AS OF 2026-03-31

1.6%

BALLAST SMALL/MID CAP ETF

$2.4M POSITION · AS OF 2026-03-31

1.5%

Virtus KAR Small-Cap Growth Series

$609.8K POSITION · AS OF 2026-03-31

1.4%

ACUITAS US MICROCAP FUND

$1.2M POSITION · AS OF 2026-03-31

1.2%

JOHNSON OPPORTUNITY FUND

$1.7M POSITION · AS OF 2026-03-31

1.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$780.6K

$569.7K

+268%

—

2024

$689.6K

$825.8K

+105%

—

2023

$642.6K

$932.3K

+75%

—

2022

$586.0K

$666.7K

-37%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$83.8M	$73.2M	$65.6M	$53.3M
GROSS PROFIT	$64.3M	$56.4M	$50.2M	$41.3M
OPERATING INCOME	$26.1M	$22.0M	$20.0M	$15.6M
NET INCOME	$22.5M	$19.2M	$17.2M	$12.8M
EPS (DILUTED)	1.75	1.50	1.35	1.02
OPERATING CASH FLOW	$24.9M	$25.6M	$13.5M	$10.0M
CASH	$51.2M	$52.2M	$49.8M	$58.0M
DIVIDENDS PAID	$15.0M	$13.7M	$13.2M	$12.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE